Company news

ProMIS Neurosciences Inc. news in 2026

ProMIS Neurosciences Inc.'s news releases, calls and decks from 2026, newest first.

View company

ProMIS Neurosciences to Participate in Upcoming Conferences in November

November 5, 2026

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

November 3, 2026

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

October 6, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

September 1, 2026

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

July 27, 2026

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

July 13, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in June

May 28, 2026

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

May 12, 2026

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

March 24, 2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

March 17, 2026

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

January 30, 2026

Decks in 2026